Theravance Biopharma, Inc.

Total Valuation

Theravance Biopharma, Inc. carries a market capitalization of 820.72M, placing it among publicly traded companies globally. Its enterprise value stands at 468.88M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Theravance Biopharma, Inc. currently has 51.51M shares outstanding.

Valuation Ratios

Theravance Biopharma, Inc. trades at a trailing price-to-earnings ratio of 7.19. The price-to-sales ratio is 7.50, and the price-to-book ratio stands at -0.95.

Enterprise Valuation

On an enterprise value basis, Theravance Biopharma, Inc. trades at an EV/EBITDA multiple of 61.90 and an EV/FCF ratio of 1.73. The EV/Sales ratio of 4.27 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 94.13 provides insight into valuation relative to core operating earnings.

Financial Position

Theravance Biopharma, Inc. maintains a current ratio of 13.14, meaning it holds 13.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 13.94, indicating elevated leverage, while an interest coverage ratio of 4.17 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Theravance Biopharma, Inc. has paid 22.37M in income taxes, reflecting an effective tax rate of 16.34.

Stock Price Statistics

Theravance Biopharma, Inc.'s stock has gained approximately 43.16547% over the past 52 weeks. The 50-day moving average sits at 16.32, while the 200-day moving average is 16.48.

Income Statement

Over the trailing twelve months, Theravance Biopharma, Inc. generated 109.78M in revenue and converted that into 114.54M in net income, yielding earnings per share of 2.21. EBITDA reached 7.58M, while operating income came in at 4.98M.

Balance Sheet

Theravance Biopharma, Inc. holds 394.67M in cash and equivalents against 40.50M in total debt, resulting in a net debt position of -288.10M. Total book value stands at -864.56M, with working capital of 385.86M providing operational flexibility.

Cash Flow

Theravance Biopharma, Inc. produced 268.78M in operating cash flow over the past twelve months. After subtracting -42,000.00 in capital expenditures, free cash flow totaled 268.74M - equivalent to 5.30 per share.

Margins

Theravance Biopharma, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of 4.54 and net profit margin of 104.34 provide insight into operational efficiency.

Dividends & Yields

Scores

Theravance Biopharma, Inc. posts an Altman Z-Score of 1.40, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.